This 12 months’s ASCO confirmed us that whereas COVID-19 is likely to be entrance and centre of everybody’s minds, the need to see actual change in most cancers remedy hasn’t diminished. In this situation of Deep Dive, Jennifer Harris from Syneos Health discusses the largest takeaways from the convention with Richard Staines.
We additionally check out how COVID-19 is affecting most cancers trials, and what the trade can do to unravel these points.
Plus we now have views and evaluation from a number of most cancers consultants – together with contributors from GSK, Accenture, ICON and Advanced Clinical – on how they suppose the long run of oncology will play out.
Rethinking oncology from the bottom up
Could we view oncology from a totally contemporary perspective? That’s the philosophy John Fleming desires to carry to GSK because it rethinks its method to most cancers
Despite going digital, this 12 months’s ASCO was full of groundbreaking analysis, as pharma finds new methods to harness the ability of the immune system to combat most cancers
Adapting for the long run of oncology
Andreas Dreps and Martin Lachs from ICON give us their ideas on the long run of most cancers analysis and the necessity for revolutionary trials
Making it as an oncology biotech within the UK
We converse to R&D consultants to learn the way oncology biotechs can get the help they want
Solving immuno-oncology trial challenges throughout COVID-19
The COVID-19 pandemic has positioned immense stress on healthcare provision, however the emergency might also make main advances in most cancers remedy much more related – if research can proceed to enhance
Clinical choice help instruments will assist oncologists handle complexity
Accenture’s Boris Bogdan and Sandra Dietschy-Künzle have a look at how instruments for physicians may assist increase adoption of immuno-oncology medicines
How to extend haematologists’ and oncologists’ confidence with new remedies
A Medscape report highlights the difficulties oncologists face in maintaining with fast developments in remedy
Commercialising revolutionary medicines
As pharma ingenuity hits new heights, guaranteeing affected person entry to medicines requires a novel mixture of proof era and communication
• Read the most recent situation Deep Dive: The Future of Oncology in full
pharmaphorum’s digital journal Deep Dive offers goal, issue-driven views, evaluation, high-level interviews and distinctive analysis for pharmaceutical firms, biotech corporations and the broader healthcare sector.
In 2020 Deep Dive can have particular focuses on disruptive applied sciences in pharma, R&D innovation, market entry and commercialisation, oncology, gross sales & advertising innovation, digital well being and affected person engagement. Subscribe to future points of Deep Dive.